9 research outputs found

    Kajian Kinerja Bagian Jalinan (Studi Kasus : Jl. Niaga 1 – Jl. Yos Sudarso, Kota Tarakan)

    Full text link
    This study aims to determine the performance on a single weave that occurred on Jl.Niaga I - Jl. Yos Sudarso, Tarakan City. The performance is capacity, degree of saturation, speed, and travel time. With these performance parameters serve as based of planning in transportation infrastructure. The results of this study are also expected to provide recommendations to users, planners and policy makers in an effort to solve traffic problems, especially to reduce the delay that occurs in a single wave that occurred on Jl Niaga I-Jl. Yos Sudarso Kota Tarakan

    Accidents preventive practice for high-rise construction

    Get PDF
    The demand of high-rise projects continues to grow due to the reducing of usable land area in Klang Valley, Malaysia.The rapidly development of high-rise projects has leaded to the rise of fatalities and accidents.An accident that happened in a construction site can cause serious physical injury.The accidents such as people falling from height and struck by falling object were the most frequent accidents happened in Malaysian construction industry.The continuous growth of high-rise buildings indicates that there is a need of an effective safety and health management. Hence, this research aims to identify the causes of accidents and the ways to prevent accidents that occur at high-rise building construction site.Qualitative method was employed in this research. Interview surveying with safety officers who are involved in highrise building project in Kuala Lumpur were conducted in this research. Accidents were caused by man-made factors, environment factors or machinery factors.The accidents prevention methods were provide sufficient Personal Protective Equipment (PPE), have a good housekeeping, execute safety inspection, provide safety training and execute accidents investigation.In the meanwhile, interviewees have suggested the new prevention methods that were develop a proper site layout planning and de-merit and merit system among subcontractors, suppliers and even employees regarding safety at workplace matters.This research helps in explaining the causes of accidents and identifying area where prevention action should be implemented, so that workers and top management will increase awareness in preventing site accidents

    Empagliflozin in Patients with Chronic Kidney Disease

    No full text
    Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo

    The surgical safety checklist and patient outcomes after surgery: a prospective observational cohort study, systematic review and meta-analysis